cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancy: initial report from shiraz surgical oncology group

Background: hyperthermic intraperitoneal chemotherapy (hipec) is increasingly used to treat peritoneal carcinomatosis (pc). the objective was to evaluate the outcomes of cytoreductive surgery (crs) and hipec in our center. method: in this retrospective study, data were collected from 43 patients with pc who underwent crs-hipec in 2016 at faghihi hospital of shiraz university of medical sciences. outcomes were collected and analyzed. analyses were conducted through spss 23. p-value < 0.05 was considered to be statistically significant. results: the mean age of the patients was 52.23 ± 11.82 years. the participants in the study analysis consisted of 36 female (83.7%) and seven male patients (16.3%). the most common primary tumor was ovarian cancer (62.8%). completeness of the cytoreduction score of cc0/cc1 was obtained in 87.7% of the patients. the 1- and 3- year overall survivals were 88% and 60%, respectively. conclusion: our study supports that employing crs and hipec for pc is feasible with acceptable morbidity in our center.